ATE203766T1 - Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose - Google Patents

Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose

Info

Publication number
ATE203766T1
ATE203766T1 AT97917668T AT97917668T ATE203766T1 AT E203766 T1 ATE203766 T1 AT E203766T1 AT 97917668 T AT97917668 T AT 97917668T AT 97917668 T AT97917668 T AT 97917668T AT E203766 T1 ATE203766 T1 AT E203766T1
Authority
AT
Austria
Prior art keywords
vhl
gene
lindau
von hippel
disease diagnosis
Prior art date
Application number
AT97917668T
Other languages
English (en)
Inventor
Marston W Linehan
Michael I Lerman
Farida Latif
Berton Zbar
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE203766T1 publication Critical patent/ATE203766T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
AT97917668T 1996-03-28 1997-03-27 Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose ATE203766T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/623,428 US6312890B1 (en) 1993-05-14 1996-03-28 Partial intron sequence of von hippel-lindau (VHL) disease gene and its use in diagnosis of disease
PCT/US1997/005059 WO1997035978A1 (en) 1996-03-28 1997-03-27 Partial intron sequence of von hippel-lindau (vhl) disease gene and its use in diagnosis of disease

Publications (1)

Publication Number Publication Date
ATE203766T1 true ATE203766T1 (de) 2001-08-15

Family

ID=24498052

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97917668T ATE203766T1 (de) 1996-03-28 1997-03-27 Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose

Country Status (8)

Country Link
US (1) US6312890B1 (de)
EP (1) EP0889959B1 (de)
JP (1) JP2000507823A (de)
AT (1) ATE203766T1 (de)
AU (1) AU2593197A (de)
CA (1) CA2250452A1 (de)
DE (1) DE69705936D1 (de)
WO (1) WO1997035978A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000037636A1 (en) * 1998-12-21 2000-06-29 The Walter And Eliza Hall Institute Of Medical Research Socs-box containing peptides
EP1307595A4 (de) * 2000-08-09 2004-09-29 Dzgenes Llc Diagnostische polymorphismen des vhl-promotors
US20040166491A1 (en) * 2001-08-09 2004-08-26 Henderson Lee A Vhl promoter diagnostic polymorphism
US20050208023A1 (en) * 2002-07-19 2005-09-22 Krissansen Geoffrey W Tumor treating composition and methods
WO2006044779A1 (en) * 2004-10-14 2006-04-27 Northwestern University Detection and treatment of renal cancer
US7549447B1 (en) * 2007-12-01 2009-06-23 Joe Garbo Pressure valve inlet cover system
KR101064603B1 (ko) 2008-11-13 2011-09-15 한국생명공학연구원 리포터 시스템을 이용한 메틸트렌스퍼레이즈 저해 물질 스크리닝 방법
US9637796B2 (en) 2011-11-17 2017-05-02 The Johns Hopkins University Differential identification of pancreatic cysts
ES2694296T3 (es) * 2014-06-17 2018-12-19 Centre National De La Recherche Scientifique (Cnrs) Anticuerpos monoclonales anti-pVHL y usos de los mismos
CN105087808A (zh) * 2015-09-15 2015-11-25 北京大学第一医院 一种检测vhl基因突变的方法及试剂盒
CN105063231A (zh) * 2015-09-15 2015-11-18 北京大学第一医院 一种羊水中胎儿细胞vhl基因突变检测方法及试剂盒
CN105087809A (zh) * 2015-09-15 2015-11-25 北京大学第一医院 一种快速检测羊水中胎儿细胞vhl基因突变的方法及试剂盒
CN105112532A (zh) * 2015-09-15 2015-12-02 北京大学第一医院 一种检测vhl基因大片段缺失的杂交探针及检测方法与试剂盒
CN113913529A (zh) * 2021-12-01 2022-01-11 济南艾迪康医学检验中心有限公司 检测VHL基因c.-195G>A位点突变的方法、引物和试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654138A (en) * 1993-05-14 1997-08-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Von hippel-lindau (VHL) disease gene and corresponding cDNA and methods for detecting carriers of the VHL disease gene

Also Published As

Publication number Publication date
US6312890B1 (en) 2001-11-06
CA2250452A1 (en) 1997-10-02
DE69705936D1 (de) 2001-09-06
JP2000507823A (ja) 2000-06-27
WO1997035978A1 (en) 1997-10-02
EP0889959B1 (de) 2001-08-01
AU2593197A (en) 1997-10-17
EP0889959A1 (de) 1999-01-13

Similar Documents

Publication Publication Date Title
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
DE69729473D1 (de) Pharmazeutisch-genetische verfahren zur verwendung bei der behandlung von krankheiten des nervensystems
ATE275383T1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69333348D1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
DE3579113D1 (de) Zusammensetzungen zur milderung, behandlung und bestimmungung von arthritschen krankheiten und aehnlichen zustaenden.
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69333931D1 (de) Verwendung von Krillenzymen zur Behandlung von Zahnbelag
NO20011283D0 (no) Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon
Motaei et al. Molecular genetics of cleidocranial dysplasia
GR3030876T3 (en) VON HIPPEL-LINDAU (VHL) DISEASE GENE AND CORRESPONDING cDNA AND METHODS FOR DETECTING CARRIERS OF THE VHL DISEASE GENE
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
EP0871457A4 (de) Isolierte stromazellen und methoden zu deren verwendung
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
DE60035693D1 (de) Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
ATE256753T1 (de) Genetischer test zur bestimmung der nicht- wirksamkeit einer behandlung mit statinmedikamenten
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
Raza et al. A novel homozygous nonsense mutation in the PVRL4 gene and expansion of clinical spectrum of EDSS1
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE375389T1 (de) Verfahren zur diagnose, prognose und behandlung von glaukom und verwandten erkrankungen
DE3688528D1 (de) Optische analoge datenverarbeitungsanordnungen zur behandlung von bipolaren und komplexen daten.
EP1009768A4 (de) Persephin und verwandte wachstumsfaktoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties